Literature DB >> 25740822

Tumor-promoting/progressing role of additional chromosome instability in hepatic carcinogenesis in Sgo1 (Shugoshin 1) haploinsufficient mice.

Hiroshi Y Yamada1, Yuting Zhang2, Arun Reddy2, Altaf Mohammed2, Stan Lightfoot2, Wei Dai3, Chinthalapally V Rao1.   

Abstract

A major etiological risk factor for hepatocellular carcinoma (HCC) is infection by Hepatitis viruses, especially hepatitis B virus and hepatitis C virus. Hepatitis B virus and hepatitis C virus do not cause aggressive activation of an oncogenic pathway, but they transactivate a broad array of genes, cause chronic inflammation, and, through interference with mitotic processes, lead to mitotic error-induced chromosome instability (ME-CIN). However, how ME-CIN is involved in the development of HCC remains unclear. Delineating the effect of ME-CIN on HCC development should help in identifying measures to combat HCC. In this study, we used ME-CIN model mice haploinsufficient in Shugoshin 1 (Sgo1(-/+)) to assess the role of ME-CIN in HCC development. Treatment with the carcinogen azoxymethane caused Sgo1(-/+) ME-CIN model mice to develop HCCs within 6 months, whereas control mice developed no HCC (P < 0.003). The HCC development was associated with expression of early HCC markers (glutamine synthetase, glypican 3, heat shock protein 70, and the serum marker alpha fetoprotein), although without fibrosis. ME-CIN preceded the expression of HCC markers, suggesting that ME-CIN is an important early event in HCC development. In 12-month-old untreated Sgo1 mice, persistent DNA damage, altered gene expression, and spontaneous HCCs were observed. Sgo1 protein accumulated in response to DNA damage in vitro. Overall, Sgo1(-/+)-mediated ME-CIN strongly promoted/progressed development of HCC in the presence of an initiator carcinogen, and it had a mild initiator effect by itself. Use of the ME-CIN model mice should help in identifying drugs to counteract the effects of ME-CIN and should accelerate anti-HCC drug development.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25740822      PMCID: PMC4392605          DOI: 10.1093/carcin/bgv011

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  48 in total

Review 1.  Diverse roles of hepatitis B virus in liver cancer.

Authors:  Guillaume Fallot; Christine Neuveut; Marie-Annick Buendia
Journal:  Curr Opin Virol       Date:  2012-06-19       Impact factor: 7.090

Review 2.  Animal models for the study of hepatitis C virus infection and related liver disease.

Authors:  Jens Bukh
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

Review 3.  Chromosomal instability and human hepatocarcinogenesis.

Authors:  N Nishida; T Nishimura; T Ito; T Komeda; Y Fukuda; K Nakao
Journal:  Histol Histopathol       Date:  2003-07       Impact factor: 2.303

4.  Azoxymethane-induced fulminant hepatic failure in C57BL/6J mice: characterization of a new animal model.

Authors:  K A Matkowskyj; J A Marrero; R E Carroll; A V Danilkovich; R M Green; R V Benya
Journal:  Am J Physiol       Date:  1999-08

5.  National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers.

Authors:  Catharine M Sturgeon; Michael J Duffy; Barry R Hofmann; Rolf Lamerz; Herbert A Fritsche; Katja Gaarenstroom; Johannes Bonfrer; Thorsten H Ecke; H Barton Grossman; Peter Hayes; Ralf-Thorsten Hoffmann; Seth P Lerner; Florian Löhe; Johanna Louhimo; Ihor Sawczuk; Kazuhisa Taketa; Eleftherios P Diamandis
Journal:  Clin Chem       Date:  2010-03-05       Impact factor: 8.327

6.  Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders.

Authors:  Darren J Baker; Tobias Wijshake; Tamar Tchkonia; Nathan K LeBrasseur; Bennett G Childs; Bart van de Sluis; James L Kirkland; Jan M van Deursen
Journal:  Nature       Date:  2011-11-02       Impact factor: 49.962

7.  Vertebrate shugoshin links sister centromere cohesion and kinetochore microtubule stability in mitosis.

Authors:  Adrian Salic; Jennifer C Waters; Timothy J Mitchison
Journal:  Cell       Date:  2004-09-03       Impact factor: 41.582

Review 8.  Aneuploidy, polyploidy and ploidy reversal in the liver.

Authors:  Andrew W Duncan
Journal:  Semin Cell Dev Biol       Date:  2013-01-16       Impact factor: 7.727

9.  Adiponectin deficiency enhances colorectal carcinogenesis and liver tumor formation induced by azoxymethane in mice.

Authors:  Tamao Nishihara; Miyako Baba; Morihiro Matsuda; Masahiro Inoue; Yasuko Nishizawa; Atsunori Fukuhara; Hiroshi Araki; Shinji Kihara; Tohru Funahashi; Shinji Tamura; Norio Hayashi; Hiroyasu Iishi; Iichiro Shimomura
Journal:  World J Gastroenterol       Date:  2008-11-14       Impact factor: 5.742

10.  Overexpression of hepatitis C virus NS5A protein induces chromosome instability via mitotic cell cycle dysregulation.

Authors:  Kwan-Hyuck Baek; Hye-Young Park; Chang-Mo Kang; So-Jung Kim; Sook-Jung Jeong; Eun-Kyung Hong; Joong-Won Park; Young-Chul Sung; Tetsuro Suzuki; Chang-Min Kim; Chang-Woo Lee
Journal:  J Mol Biol       Date:  2006-03-29       Impact factor: 5.469

View more
  15 in total

Review 1.  Critical role of mitosis in spontaneous late-onset Alzheimer's disease; from a Shugoshin 1 cohesinopathy mouse model.

Authors:  Chinthalapally V Rao; Mudassir Farooqui; Adam S Asch; Hiroshi Y Yamada
Journal:  Cell Cycle       Date:  2018-09-20       Impact factor: 4.534

Review 2.  Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes.

Authors:  Yuan-Chi Teng; Zhao-Qing Shen; Cheng-Heng Kao; Ting-Fen Tsai
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 3.  Role of E2Fs and mitotic regulators controlled by E2Fs in the epithelial to mesenchymal transition.

Authors:  Shirley Jusino; Harold I Saavedra
Journal:  Exp Biol Med (Maywood)       Date:  2019-10-01

4.  SGO1 induces proliferation and metastasis of prostate cancer through AKT-mediated signaling pathway.

Authors:  Qi Chen; Xiang Wan; Yanbo Chen; Chong Liu; Meng Gu; Zhong Wang
Journal:  Am J Cancer Res       Date:  2019-12-01       Impact factor: 6.166

5.  The expanding phenotypes of cohesinopathies: one ring to rule them all!

Authors:  Jessica Piché; Patrick Piet Van Vliet; Michel Pucéat; Gregor Andelfinger
Journal:  Cell Cycle       Date:  2019-09-13       Impact factor: 4.534

Review 6.  Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer.

Authors:  Chinthalapally V Rao; Adam S Asch; Hiroshi Y Yamada
Journal:  Carcinogenesis       Date:  2016-11-12       Impact factor: 4.944

7.  Genomic instability genes in lung and colon adenocarcinoma indicate organ specificity of transcriptomic impact on Copy Number Alterations.

Authors:  Chinthalapally V Rao; Chao Xu; Yuting Zhang; Adam S Asch; Hiroshi Y Yamada
Journal:  Sci Rep       Date:  2022-07-11       Impact factor: 4.996

8.  Systemic Chromosome Instability Resulted in Colonic Transcriptomic Changes in Metabolic, Proliferation, and Stem Cell Regulators in Sgo1-/+ Mice.

Authors:  Chinthalapally V Rao; Saira Sanghera; Yuting Zhang; Laura Biddick; Arun Reddy; Stan Lightfoot; Naveena B Janakiram; Altaf Mohammed; Wei Dai; Hiroshi Y Yamada
Journal:  Cancer Res       Date:  2016-02-01       Impact factor: 12.701

9.  Survival-Critical Genes Associated with Copy Number Alterations in Lung Adenocarcinoma.

Authors:  Chinthalapally V Rao; Chao Xu; Mudassir Farooqui; Yuting Zhang; Adam S Asch; Hiroshi Y Yamada
Journal:  Cancers (Basel)       Date:  2021-05-25       Impact factor: 6.639

10.  High SGO2 Expression Predicts Poor Overall Survival: A Potential Therapeutic Target for Hepatocellular Carcinoma.

Authors:  Min Deng; Shaohua Li; Jie Mei; Wenping Lin; Jingwen Zou; Wei Wei; Rongping Guo
Journal:  Genes (Basel)       Date:  2021-06-07       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.